It’s a fairly common occurrence for ASX-listed companies to start slowing down their operations as the holiday season draws near – but not so for Paradigm Biopharmaceuticals (ASX:PAR), which only just last week both successfully recruited and dosed Australian and U.S. patients in its Phase III clinical trials.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This content is disseminated in partnership with Paradigm Biopharmaceuticals Ltd. It is intended to inform investors and should not be taken as a recommendation or financial advice.
With this trial, and many other irons in the fire, there’s no time to rest for Paradigm as it chases aspirations to treat medical needs like osteoarthritis.
To discuss the busy coming months and many moving parts for the pharma developer, HotCopper welcomed company managing director Paul Rennie to a Capital Compass deep-dive – and you can watch the full video above.
PAR is selling at 39.5cps today and has been up +43% in the last month.
Join the discussion. See what HotCopper users are saying about Paradigm Biopharmaceuticals Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.